Anti-CRBN antibody produced in mouse

Cereblon (CRBN) is encoded by the gene mapped to human chromosome 3p26.2. It is ubiquitously expressed in various subcellular compartments such as nucleus, cytoplasm and endoplasmic reticulum (ER).

CRBN (NP_057386.2, 1 a.a. ~ 442 a.a) full-length human protein.

Sequence
MAGEGDQQDAAHNMGNHLPLLPAESEEEDEMEVEDQDSKEAKKPNIINFDTSLPTSHTYLGADMEEFHGRTLHDDDSCQVIPVLPQVMMILIPGQTLPLQLFHPQEVSMVRNLIQKDRTFAVLAYSNVQEREAQFGTTAEIYAYREEQDFGIEIVKVKAIGRQRFKVLELRTQSDGIQQAKVQILPECVLPSTMSAVQLESLNKCQIFPSKPVSREDQCSYKWWQKYQKRKFHCANLTSWPRWLYSLYDAETLMDRIKKQLREWDENLKDDSLPSNPIDFSYRVAACLPIDDVLRIQLLKIGSAIQRLRCELDIMNKCTSLCCKQCQETEITTKNEIFSLSLCGPMAAYVNPHGYVHETLTVYKACNLNLIGRPSTEHSWFPGYAWTVAQCKICASHIGWKFTATKKDMSPQKFWGLTRSALLPTIPDTEDEISPDKVILCL

Anti-CRBN antibody produced in mouse has been used in western blotting.

Cereblon (CRBN) is a substrate binding component of the E3 ubiquitin ligase complex. It interacts with thalidomide and its analog to facilitate proteasome-dependent degradation of the transcription factors, Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3). CRBN provides cytoprotection against the ubiquitin-proteasome system-dysfunction. It negatively regulates the AMP-activated protein kinase signaling pathway in vivo. Nonsense mutation of the CRBN gene causes mild type of autosomal recessive nonsyndromic intellectual disability (ID).

Solution in phosphate buffered saline, pH 7.4

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.